Patron Exim Ltd
Incorporated in 1992, Patron Exim Ltd is in the business of trading pharma products and commission agent in pharma products, etc.[1]
- Market Cap ₹ 7.00 Cr.
- Current Price ₹ 3.02
- High / Low ₹ 9.92 / 2.92
- Stock P/E 21.2
- Book Value ₹ 16.9
- Dividend Yield 0.00 %
- ROCE 0.28 %
- ROE 0.18 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.18 times its book value
- Debtor days have improved from 349 to 91.6 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -51.2%
- Promoter holding is low: 20.0%
- Company has a low return on equity of 2.12% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Trading - Chemicals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 3.88 | 12.95 | 6.58 | 24.36 | 48.08 | |
| 3.41 | 16.92 | 9.33 | 24.57 | 47.83 | |
| Operating Profit | 0.47 | -3.97 | -2.75 | -0.21 | 0.25 |
| OPM % | 12.11% | -30.66% | -41.79% | -0.86% | 0.52% |
| 1.14 | 5.93 | 3.65 | 0.32 | 0.13 | |
| Interest | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 1.41 | 1.95 | 0.90 | 0.11 | 0.38 |
| Tax % | 30.50% | 29.23% | 25.56% | 36.36% | |
| 0.99 | 1.38 | 0.67 | 0.07 | 0.33 | |
| EPS in Rs | 0.60 | 0.29 | 0.03 | 0.14 | |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 84% |
| TTM: | 804% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -59% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -62% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 2% |
| Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 5.34 | 23.18 | 23.18 | 23.18 | 23.18 |
| Reserves | 0.00 | 15.29 | 15.96 | 16.03 | 16.04 |
| 0.00 | 0.03 | 0.26 | 0.23 | 2.15 | |
| 5.62 | -0.02 | 5.93 | 4.81 | 11.32 | |
| Total Liabilities | 10.96 | 38.48 | 45.33 | 44.25 | 52.69 |
| 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 8.67 | 8.67 | 8.76 | 8.80 |
| 10.95 | 29.80 | 36.65 | 35.48 | 43.89 | |
| Total Assets | 10.96 | 38.48 | 45.33 | 44.25 | 52.69 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 0.76 | -22.81 | -0.26 | -0.01 | |
| 0.00 | -8.68 | 0.00 | 0.00 | |
| -0.76 | 31.78 | 0.23 | -0.03 | |
| Net Cash Flow | 0.00 | 0.29 | -0.04 | -0.04 |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 710.24 | 393.75 | 561.92 | 91.55 |
| Inventory Days | 336.84 | 89.82 | 308.75 | 42.61 |
| Days Payable | 537.21 | -23.95 | 625.34 | 61.07 |
| Cash Conversion Cycle | 509.87 | 507.52 | 245.33 | 73.09 |
| Working Capital Days | 500.46 | 831.19 | 1,674.67 | 452.80 |
| ROCE % | 8.90% | 2.31% | 0.28% |
Documents
Announcements
-
Statement Of Deviation For The Half Year Ended September 30, 2025.
12 Nov - No deviation in IPO fund utilization (Rs16.68 crore) for half-year ended 30 Sep 2025.
- Unaudited Results For The Half Year Ended September 30, 2025 12 Nov
-
Board Meeting Outcome for Board Meeting Outcome For Half Yearly Results As On September 30, 2025.
12 Nov - Board approved standalone unaudited H1 results to Sept 30,2025: revenue Rs.2,372.11 lakh; profit Rs.1.49 lakh.
-
Update on board meeting
7 Nov - Board meeting on 12 Nov 2025 to approve Q2/H1 unaudited standalone results; trading window closed.
-
Board Meeting Intimation for Half Yearly Financial Results As On September 30, 2025 And Other General Business Matters
6 Nov - Board meeting on 12 Nov 2025 to approve unaudited Q2/H1 financial results ended 30 Sep 2024.
Business Overview:[1]
PEL used to do trading of timber, cement sheets and other ancillary business, and also in surgical & non-surgical articles. Currently, company is an ISO 9001:2015, ISO 45001:2018, WHO-GMP, etc. certified trader and distributor of wide range of pharmaceutical raw material like Active Pharmaceutical Ingredients, Industrial, excipient, and solvents